| Wall Street Analysts Believe Seres Therapeutics (MCRB) Could Rally 713.09%: Here's is How to Trade |
The mean of analysts' price targets for Seres Therapeutics (MCRB) points to a 713.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock. |
zacks.com |
2025-05-16 15:01:12 |
Czytaj oryginał (ang.) |
| Seres Therapeutics, Inc. (MCRB) Q1 2025 Earnings Call Transcript |
Seres Therapeutics, Inc. (NASDAQ:MCRB ) Q1 2025 Earnings Call May 7, 2025 8:30 AM ET Company Participants Carlo Tanzi - Investor Relations Eric Shaff - President and Chief Executive Officer Marella Thorell - Chief Financial Officer Matthew Henn - Chief Scientific Officer Terri Young - Chief Commercial and Strategy Officer Dennis Walling - Senior Vice President, Clinical Development Conference Call Participants Caroline Pötsch-Hennig - JPMorgan Joseph Thome - TD Cowen John Newman - Canaccord Operator Ladies and gentlemen, thank you for standing by. My name is Desiree, and I will be your conference operator today. |
seekingalpha.com |
2025-05-07 18:18:22 |
Czytaj oryginał (ang.) |
| Seres Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Updates |
In line with recent FDA feedback, Seres expects to submit a Phase 2 study protocol to FDA in the coming weeks for SER-155 for the prevention of bloodstream infections (BSIs) in adults undergoing allogeneic hematopoietic stem cell transplant (allo-HSCT) for the treatment of hematological malignancies SER-155 Phase 1b placebo-controlled study exploratory translational biomarker data reinforce intended mechanisms of action, consistent with clinical results that showed a significant reduction (77% relative risk reduction) in BSIs, and support broader potential for Seres' live biotherapeutics to address inflammatory and immune diseases Seres advancing SER-155 strategic partnership discussions in support of further development in allo-HSCT and potential expansion into other target populations Conference call at 8:30 a.m. ET today CAMBRIDGE, Mass. |
globenewswire.com |
2025-05-07 11:00:00 |
Czytaj oryginał (ang.) |
| Seres Therapeutics Presents Data at the 2025 Digestive Disease Week Conference Highlighting the Potential for Live Biotherapeutics to Treat Inflammatory and Immune Diseases |
CAMBRIDGE, Mass., April 29, 2025 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading live biotherapeutics company, today announced that it will present three related posters at the upcoming 2025 Digestive Disease Week (DDW) Conference being held May 3-6, 2025, in San Diego, CA. |
globenewswire.com |
2025-04-29 11:00:00 |
Czytaj oryginał (ang.) |
| Seres Therapeutics to Announce First Quarter 2025 Financial Results and Business Updates on May 7, 2025 |
CAMBRIDGE, Mass., April 23, 2025 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading live biotherapeutics company, today announced that management will host a conference call and live audio webcast on May 7, 2025 at 8:30 a.m. ET to discuss first quarter 2025 financial results and provide business updates. |
globenewswire.com |
2025-04-23 11:00:00 |
Czytaj oryginał (ang.) |
| Down -48.7% in 4 Weeks, Here's Why Seres Therapeutics (MCRB) Looks Ripe for a Turnaround |
Seres Therapeutics (MCRB) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock. |
zacks.com |
2025-04-17 14:35:35 |
Czytaj oryginał (ang.) |
| Seres Therapeutics, Inc. (MCRB) Q4 2024 Earnings Call Transcript |
Seres Therapeutics, Inc. (NASDAQ:MCRB ) Q4 2024 Earnings Conference Call March 13, 2025 8:30 AM ET Company Participants Carlo Tanzi - Kendall Investor Relations Eric Shaff - President and Chief Executive Officer Lisa von Moltke - Executive Vice President and Chief Medical Officer Matthew Henn - Executive Vice President and Chief Scientific Officer Terri Young - Executive Vice President, Chief Commercial and Strategy Officer Marella Thorell - Executive Vice President and Chief Financial Officer Chris McChalicher - Senior Vice President, Manufacturing, Quality and Process Development Conference Call Participants Joseph Thome - TD Cowen Caroline Pocher - JPMorgan Edward Tenthoff - Piper Sandler John Newman - Canaccord Genuity Operator Thank you for standing by. My name is Kate, and I will be your conference operator today. |
seekingalpha.com |
2025-03-13 13:04:29 |
Czytaj oryginał (ang.) |
| Seres Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates |
Recent FDA feedback received on SER-155 allogeneic hematopoietic stem cell transplant (allo-HSCT) next study provides support for the proposed primary efficacy endpoint of reduction in bloodstream infections (BSIs) at day 30 post-HSCT; Company expects to submit draft study protocol to FDA in Q2 2025 |
globenewswire.com |
2025-03-13 09:00:00 |
Czytaj oryginał (ang.) |
| Seres Therapeutics to Announce Fourth Quarter and Full Year 2024 Financial Results and Provide Business Updates on March 13, 2025 |
CAMBRIDGE, Mass., March 04, 2025 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading live biotherapeutics company, today announced that management will host a conference call and live audio webcast on March 13, 2025 at 8:30 a.m. |
globenewswire.com |
2025-03-04 09:00:00 |
Czytaj oryginał (ang.) |
| Seres Therapeutics Receives Feedback From FDA on SER-155 Allogeneic Hematopoietic Stem Cell Transplant (allo-HSCT) Development Approach |
FDA has provided input on key elements of the SER-155 allo-HSCT clinical development plans including support for the proposed primary efficacy endpoint of reduction in bloodstream infections (BSIs) as of 30 days post HSCT in the next study |
globenewswire.com |
2025-03-03 09:00:00 |
Czytaj oryginał (ang.) |
| Seres Therapeutics Announces Receipt of Expected $50 Million Installment Payment Related to VOWST Sale |
CAMBRIDGE, Mass., Jan. 16, 2025 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB) (Seres or the Company), a leading live biotherapeutics company, announced today the receipt of a $50 million installment payment related to the Company's previously announced sale of its VOWST business to Société des Produits Nestlé S.A (SPN, and with certain of its affiliates, collectively, Nestlé Health Science). This installment payment was expected as Seres is fulfilling its transition obligations. |
globenewswire.com |
2025-01-16 09:00:00 |
Czytaj oryginał (ang.) |
| Seres Therapeutics Announces New Translational Biomarker Results from SER-155 Phase 1b Clinical Study and Provides Corporate Updates |
New SER-155 Phase 1b study biomarker data in allogeneic hematopoietic stem cell transplantation (allo-HSCT) recipients demonstrate that SER-155 promoted epithelial barrier integrity and decreased systemic inflammatory biomarkers compared to placebo; data support the broader potential of Seres' live biotherapeutics to target inflammatory and immune diseases |
globenewswire.com |
2025-01-09 09:00:00 |
Czytaj oryginał (ang.) |
| Seres Therapeutics to Participate in 2025 J.P. Morgan Healthcare Conference |
CAMBRIDGE, Mass., Dec. 16, 2024 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading live biotherapeutics company, today announced that management will participate in the 43rd Annual J.P. Morgan Healthcare Conference. Eric Shaff, President and Chief Executive Officer, will present a corporate overview on January 16, 2025 at 7:30 a.m. PT. |
globenewswire.com |
2024-12-16 09:00:00 |
Czytaj oryginał (ang.) |
| Seres Therapeutics to Participate in Piper Sandler Healthcare Conference |
CAMBRIDGE, Mass., Nov. 22, 2024 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading live biotherapeutics company, today announced that Eric Shaff, President and Chief Executive Officer, will participate in a fireside chat at the Piper Sandler 36th Annual Healthcare Conference on December 3, 2024, at 4:30 p.m. ET. |
globenewswire.com |
2024-11-22 09:00:00 |
Czytaj oryginał (ang.) |
| Seres Therapeutics, Inc. (MCRB) Q3 2024 Earnings Call Transcript |
Seres Therapeutics, Inc. (NASDAQ:MCRB ) Q3 2024 Earnings Conference Call November 13, 2024 8:30 AM ET Company Participants Carlo Tanzi - Investor Relations Eric Shaff - Chief Executive Officer Lisa von Moltke - Chief Medical Officer Teresa Young - EVP, Chief Commercial & Strategy Officer, Marella Thorell - Chief Financial Officer Matthew Henn - EVP, Chief Scientific Officer Conference Call Participants Joseph Thome - TD Cowen Caroline Pocher - JPMorgan Edward Tenthoff - Piper Sandler Operator Thank you for standing by. My name is Bella, and I will be your conference operator today. |
seekingalpha.com |
2024-11-13 12:28:35 |
Czytaj oryginał (ang.) |
| Seres Therapeutics to Announce Third Quarter 2024 Financial Results and Business Updates on November 13, 2024 |
CAMBRIDGE, Mass., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading live biotherapeutics company, today announced that management will host a conference call and live audio webcast on November 13, 2024 at 8:30 a.m. ET to discuss third quarter 2024 financial results and provide business updates. |
globenewswire.com |
2024-11-06 09:00:00 |
Czytaj oryginał (ang.) |
| Seres Therapeutics Announces Completion of VOWST™ Asset Sale to Société des Produits Nestlé S.A |
Transaction supports further development of SER-155, following recent promising clinical data, and other cultivated live biotherapeutics, for multiple medically vulnerable patient populations at high risk of life-threatening bacterial infections |
globenewswire.com |
2024-09-30 21:15:00 |
Czytaj oryginał (ang.) |
| Seres Therapeutics Stockholders Issue Open Letter to Board of Directors Regarding Reported Engagement With Nestlé |
GENEVA--(BUSINESS WIRE)--Lucien Selce and MKT Capital Ltd. (together, “we”), who collectively own 1.4 million shares of Seres Therapeutics Inc. (NASDAQ: MCRB) (“Seres” or the “Company”), today published the following open letter to the Company's Board of Directors (the “Board”). *** September 27, 2024 Members of the Board, We are writing to you today as a stockholder of Seres who is seeking additional information regarding the Company's planned sale of its VOWST business to Nestlé Health Scienc. |
businesswire.com |
2024-09-27 19:26:00 |
Czytaj oryginał (ang.) |
| Seres Therapeutics Stockholders Approve Sale of VOWST™ to Nestlé Health Science; Sale Expected to Close on September 30 |
CAMBRIDGE, Mass., Sept. 26, 2024 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB), (“Seres” or the “Company”), a leading live biotherapeutics company, today announced that its stockholders voted to approve the previously announced proposed sale of the Company's VOWST business to Société des Produits Nestlé S.A. Seres will file a Current Report on Form 8-K with the SEC which details the voting results. The transaction is expected to close on September 30, 2024, subject to the satisfaction of customary closing conditions. |
globenewswire.com |
2024-09-26 20:01:00 |
Czytaj oryginał (ang.) |
| Seres Therapeutics' Strategic Sale Of Vowst Warrants A Rating Upgrade |
Seres Therapeutics' sale of VOWST to Nestlé extends its cash runway to Q4 2025, addressing near-term financial concerns. MCRB will receive a $100 million upfront payment, with approximately $20 million used to settle net obligations. It also gets potential future milestone payments of up to $275 million. Promising Phase 1b data for SER-155 shows potential in preventing bacterial infections in immunocompromised patients, positioning it as a new value driver. |
seekingalpha.com |
2024-09-23 04:14:32 |
Czytaj oryginał (ang.) |